NASDAQ:CERE Cerevel Therapeutics (CERE) Stock Forecast, Price & News $20.35 +0.09 (+0.44%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$19.85▼$20.4250-Day Range$20.26▼$30.7352-Week Range$19.85▼$35.98Volume806,648 shsAverage Volume615,277 shsMarket Capitalization$3.20 billionP/E RatioN/ADividend YieldN/APrice Target$34.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Cerevel Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside67.1% Upside$34.00 Price TargetShort InterestBearish7.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.10Based on 4 Articles This WeekInsider TradingBalancedInsiders Both Buying and SellingProj. Earnings GrowthDecreasingFrom ($2.59) to ($2.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.61 out of 5 starsMedical Sector866th out of 963 stocksPharmaceutical Preparations Industry405th out of 447 stocks 3.3 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.00, Cerevel Therapeutics has a forecasted upside of 67.1% from its current price of $20.35.Amount of Analyst CoverageCerevel Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.92% of the float of Cerevel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCerevel Therapeutics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Cerevel Therapeutics has recently increased by 7.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERE. Previous Next 1.1 News and Social Media Coverage News SentimentCerevel Therapeutics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cerevel Therapeutics this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $2,510,922.00 in company stock and sold $2,705,000.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.Percentage Held by InsidersOnly 5.10% of the stock of Cerevel Therapeutics is held by insiders.Percentage Held by Institutions87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.59) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 6.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cerevel Therapeutics (NASDAQ:CERE) StockCerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More CERE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERE Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comCerevel Therapeutics (NASDAQ:CERE) Stock Price Down 3.2%September 22, 2023 | benzinga.comParkinson's Disease Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)September 26, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 22, 2023 | americanbankingnews.comCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), ADC Therapeutics (ADCT) and Sanofi (OtherSNYNF)September 8, 2023 | benzinga.comCannabis Odor Sparks Legal Battle Impacting California Real Estate, Lawsuit Alleges NuisanceAugust 29, 2023 | finance.yahoo.comCerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 25, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Catalent (CTLT)September 26, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 23, 2023 | bizjournals.comJ&J-backed startup raises $150M in VC for neuroscience drugsAugust 11, 2023 | finance.yahoo.comInsiders Buy the Dip in These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back — Here’s Why You Should Pay AttentionAugust 9, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Revance Therapeutics (RVNC), Personalis (PSNL)August 6, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Cerevel Therapeutics Holdings (CERE)August 5, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CEREAugust 4, 2023 | msn.comCerevel: Drop On Data Delay For EMPOWER Program Provides Buy OpportunityAugust 3, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Cerevel Therapeutics Holdings (CERE), G1 Therapeutics (GTHX)August 3, 2023 | msn.comWhy Is Cerevel Therapeutics Stock Trading Lower Today?August 3, 2023 | seekingalpha.comCerevel Therapeutics falls on delayed data readoutsAugust 3, 2023 | markets.businessinsider.comCerevel Therapeutics Holdings (CERE) Receives a Hold from Berenberg BankAugust 3, 2023 | msn.comCerevel Therapeutics falls on delayed readoutAugust 2, 2023 | msn.comCerevel Therapeutics GAAP EPS of -$0.63 beats by $0.06August 2, 2023 | fool.comWhy Shares of Cerevel Therapeutics Are Dropping WednesdayAugust 2, 2023 | finance.yahoo.comCerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatesJuly 11, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Arbutus Biopharma (ABUS)July 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Ambrx Biopharma (AMAM)July 5, 2023 | finance.yahoo.comCerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023June 20, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Calliditas Therapeutics (CALT), Surface Oncology (SURF) and Crinetics Pharmaceuticals (CRNX)See More Headlines Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CERE Company Calendar Last Earnings8/02/2023Today9/26/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels SectorMedical Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees322Year FoundedN/APrice Target and Rating Average Stock Price Forecast$34.00 High Stock Price Forecast$46.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+67.1%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-351,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-83.19% Return on Assets-40.30% Debt Debt-to-Equity Ratio0.96 Current Ratio11.47 Quick Ratio11.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.33 per share Price / Book6.11Miscellaneous Outstanding Shares157,490,000Free Float149,456,000Market Cap$3.20 billion OptionableNot Optionable Beta1.42 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. N. Anthony Coles Jr. (Age 63)M.P.H., Exec. Chairman Comp: $1.14MMr. Mark Bodenrader (Age 50)VP of Fin. & Chief Accounting Officer Comp: $496.17kDr. John J. Renger Ph.D. (Age 54)Chief Scientific Officer Comp: $779.75kDr. Ramiro Sanchez M.D. (Age 62)Chief Medical Officer Comp: $805.13kMr. Ronald C. Renaud Jr. (Age 54)M.B.A., MBA, Pres, CEO & Director Dr. Susan Altschuller M.B.A. (Age 41)Ph.D., Chief Financial Officer Mr. Matthew CalistriVP of Investor RelationsMr. Scott M. Akamine J.D. (Age 38)Chief Legal Officer & Corp. Sec. Mr. Kenneth A. DiPietro (Age 64)Chief HR Officer Ms. Kathleen Tregoning M.A. (Age 52)Chief Corp. Affairs Officer More ExecutivesKey CompetitorsCorcept TherapeuticsNASDAQ:CORTAxsome TherapeuticsNASDAQ:AXSMCytokineticsNASDAQ:CYTKMoonLake ImmunotherapeuticsNASDAQ:MLTXMadrigal PharmaceuticalsNASDAQ:MDGLView All CompetitorsInsiders & InstitutionsBarclays PLCSold 469,712 shares on 9/21/2023Ownership: 0.083%N Anthony ColesSold 50,000 sharesTotal: $1.20 M ($24.07/share)Perceptive Advisors LLCBought 3,576,658 shares on 8/24/2023Ownership: 6.406%Wolverine Trading LLCSold 26,900 shares on 8/23/2023Ownership: 0.000%Affinity Asset Advisors LLCBought 170,000 shares on 8/21/2023Ownership: 0.349%View All Insider TransactionsView All Institutional Transactions CERE Stock - Frequently Asked Questions Should I buy or sell Cerevel Therapeutics stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CERE shares. View CERE analyst ratings or view top-rated stocks. What is Cerevel Therapeutics' stock price forecast for 2023? 10 equities research analysts have issued 12-month price objectives for Cerevel Therapeutics' shares. Their CERE share price forecasts range from $22.00 to $46.00. On average, they expect the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price. View analysts price targets for CERE or view top-rated stocks among Wall Street analysts. How have CERE shares performed in 2023? Cerevel Therapeutics' stock was trading at $31.54 on January 1st, 2023. Since then, CERE stock has decreased by 35.5% and is now trading at $20.35. View the best growth stocks for 2023 here. Are investors shorting Cerevel Therapeutics? Cerevel Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 5,440,000 shares, an increase of 7.1% from the August 15th total of 5,080,000 shares. Based on an average daily volume of 635,600 shares, the short-interest ratio is currently 8.6 days. Currently, 7.9% of the company's shares are sold short. View Cerevel Therapeutics' Short Interest. When is Cerevel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our CERE earnings forecast. How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) posted its earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.02. During the same quarter in the previous year, the firm earned ($0.61) EPS. What ETFs hold Cerevel Therapeutics' stock? ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), iShares Neuroscience and Healthcare ETF (IBRN), Principal Healthcare Innovators ETF (BTEC), Harbor Health Care ETF (MEDI) and Fidelity Disruptive Medicine ETF (FMED). What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO). What is Cerevel Therapeutics' stock symbol? Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE." Who are Cerevel Therapeutics' major shareholders? Cerevel Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (6.41%), BlackRock Inc. (3.08%), State Street Corp (1.76%), Artal Group S.A. (1.04%), Geode Capital Management LLC (0.86%) and Polar Capital Holdings Plc (0.58%). Insiders that own company stock include Abraham Ceesay, Deval L Patrick, Gabrielle Sulzberger, John Renger, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc and Ronald C Renaud Jr. View institutional ownership trends. How do I buy shares of Cerevel Therapeutics? Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cerevel Therapeutics' stock price today? One share of CERE stock can currently be purchased for approximately $20.35. How much money does Cerevel Therapeutics make? Cerevel Therapeutics (NASDAQ:CERE) has a market capitalization of $3.20 billion. The biotechnology company earns $-351,510,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. How many employees does Cerevel Therapeutics have? The company employs 322 workers across the globe. How can I contact Cerevel Therapeutics? Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The official website for the company is ceres.net. The biotechnology company can be reached via phone at 844-304-2048 or via email at ir@cerevel.com. This page (NASDAQ:CERE) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.